1429617-78-6

Basic information

• Product Name: C₂₅H₁₈N₆O
• CAS NO: 1429617-78-6
• Molecular Weight: 418.458
• Mol File: 1429617-78-6.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: C₂₅H₁₈N₆O(CAS DataBase Reference)
• NIST Chemistry Reference: C₂₅H₁₈N₆O(1429617-78-6)
• EPA Substance Registry System: C₂₅H₁₈N₆O(1429617-78-6)

Safety Data

• Hazardous Substances Data: 1429617-78-6(Hazardous Substances Data)

Upstream product

• 1255099-13-8 methyl 3-ethynyl-4-methylbenzoate 
• 90347-66-3 methyl 3-iodo-4-methylbenzoate 
• 1429618-01-8 4-methyl-3-(pyrazolo[1,5-a]pyrimidin-6-ylethynyl)benzoic acid 
• 112677-67-5 3-(1H-imidazol-1-yl)aniline 
• 1429617-97-9 methyl 4-methyl-3-(pyrazolo[1,5-a]pyrimidin-6-ylethynyl)benzoate 

Relevant articles and documents

Discovery and optimization of 3-(2-(Pyrazolo[1,5- a ]pyrimidin-6-yl) ethynyl)benzamides as novel selective and orally bioavailable discoidin domain receptor 1 (DDR1) inhibitors

Discoidin domain receptor 1 (DDR1) is an emerging potential molecular target for new anticancer drug discovery. We have discovered a series of 3-(2-(pyrazolo[1,5-a]pyrimidin-6-yl) ethynyl)benzamides that are selective and orally bioavailable DDR1 inhibitors. The two most promising compounds (7rh and 7rj) inhibited the enzymatic activity of DDR1, with IC50 values of 6.8 and 7.0 nM, respectively, but were significantly less potent in suppressing the kinase activities of DDR2, Bcr-Abl, and c-Kit. Further study revealed that 7rh bound with DDR1 with a Kd value of 0.6 nM, while it was significantly less potent to the other 455 kinases tested. The S(35) and S(10) selectivity scores of 7rh were 0.035 and 0.008, respectively. The compounds also potently inhibited the proliferation of cancer cells expressing high levels of DDR1 and strongly suppressed cancer cell invasion, adhesion, and tumorigenicity. Preliminary pharmacokinetic studies suggested that they possessed good PK profiles, with oral bioavailabilities of 67.4% and 56.2%, respectively.